

INFLIXIMABE NO TRATAMENTO DA PSORÍASE GRAVE

(**Psoriasis**) OR (Psoríases) OR (Pustulosis of Palms and Soles) OR (Palmoplantar Pustulosis) OR (Pustulosis Palmaris et Plantaris) OR (Pustular Psoriasis of Palms and Soles)

(**infliximab**) OR (MAb cA2) OR (monoclonal antibody cA2) OR (Remicade) OR (Centocor brand of infliximab) OR (Essex brand of infliximab) OR (Schering brand of infliximab) OR (Schering-Plough brand of infliximab)

BIREME/PAHO/WHO - Virtual Health Library

Database : **LILACS**

Search on : (**Psoriasis**) OR (**Psoríases**) OR (**Pustulosis of Palms and Soles**) OR (**Palmoplantar Pustulosis**) OR (**Pustulosis Palmaris et Plantaris**) OR (**Pustular Psoriasis of Palms and Soles**) [Words] and (**infliximab**) OR (**MAb cA2**) OR (**monoclonal antibody cA2**) OR (**Remicade**) OR (**Centocor brand of infliximab**) OR (**Essex brand of infliximab**) OR (**Schering brand of infliximab**) OR (**Schering-Plough brand of infliximab**) [Words]

Total of references : **3**

1/3

Id: 418796

Author: Loyola, Adriano Jaime Consorte; Castro, Lia Cândida Miranda de; Chaibub, Sulamita Costa Wirth; Ximenes, Antônio Carlos.

Title: Infliximab no tratamento da artrite psoriásica grave / Infliximab in treatment of severe psoriatic arthritis

Source: [An. bras. dermatol](#);80(5):535-537, set.-out. 2005. ilus.

Language: Pt.

Abstract: A artrite psoriásica tem sido reconhecida como doença imunomediada, em que há participação de células T produtoras de citocinas (fator de necrose tumoral-alfa). O infliximab é anticorpo monoclonal que se liga e inativa o fator de necrose tumoral-alfa. Relata-se um caso de artrite psoriásica grave, refratária a várias terapêuticas sistêmicas, tratado com infliximab 5mg/kg, em infusão venosa de três horas, nas semanas 0, 2, 6 e 14, associado com baixa dose de metotrexato, que apresentou excelente resposta terapêutica. (AU).

Descriptors: [Arthritis, Psoriatic](#)
[Tumor Necrosis Factor](#)
[Psoriasis](#)

Tipo de Publicação: [Comparative Study](#)

Responsible: BR461.1 - SOC.BRAS.DERMATOLOGIA/Bteca

2/3

Id: 396086

Author: Tejos Avello, Loreto; Díaz, Yolimar; Páez, Erika.

Title: Eritrodermia psoriática: respuesta al tratamiento con infliximab / Psoriatic erythroderma: answer to the treatment with infliximab

Source: [Dermatol. venez;](#)41(1):24-27, 2003. ilus, graf.

Language: Es.

Abstract: La psoriasis es una enfermedad autoinmune, crónica; que hoy se reconoce que está mediada por los linfocitos T, asociada a señales co-estimuladoras cuya función principal es la secreción de citoquinas. En la actualidad existen nuevos productos biológicos capaces de inhibir algunas citoquinas, como el factor de necrosis tumoral alfa (FNT) la cual interviene en este intrincado proceso. Presentamos una paciente de 35 años con diagnóstico de psoriasis en placa desde 1989, que recibió múltiples tratamientos (corticosteroides tópicos, derivados de la vitamina D, UVB, PUVA, metotrexano, acitretino, ciclosporina, colchicina). Desde el año 2001 presenta eritrodermia psoriática a tratamiento, por lo que se decide el uso de infliximab (anticuerpo monoclonal contra el factor de necrosis tumoral alfa) a una dosis de 3 mg/kg peso. Después de la segunda semana de haber recibido el tratamiento, experimentó una mejoría notable de la psoriasis, con una reducción de un 81 por ciento de PAST con respecto al ingreso la cual ha persistido después de 5 dosis(AU).

Descriptors: [Psoriasis/therapy](#)
[Dermatitis, Exfoliative/therapy](#)
[Antibodies, Monoclonal/therapeutic use](#)
[Tumor Necrosis Factor/therapeutic use](#)
[-Venezuela](#)
[Dermatology](#)

Limits: [Human](#)
[Adult](#)
[Female](#)

Tipo de Publicação: [Case Reports \[Publication Type\]](#)

Responsible: VE1.1 - Un.Centr.Venez/SINADIB

3/3

Id: 355980

Author: Labarca, C; Massardo, L; García, P. I; Jacobelli, S.

Title: Evaluación del tratamiento con infliximab en enfermos con artritis inflamatoria refractaria a drogas habituales / Effectiveness of infliximab in patients with inflammatory arthritis refractory to conventional treatment

Source: [Rev. méd. Chile;](#)131(10):1157-1164, oct. 2003.

Language: Es.

Abstract: BACKGROUND: Tumor necrosis factor antagonists are useful in the treatment of several chronic inflammatory immune mediated diseases. AIM: To assess the effects of infliximab in 21 patients with inflammatory arthropathies, refractory to conventional treatment. PATIENTS AND METHODS: Eleven patients with rheumatoid arthritis, seven with psoriatic arthritis and three with spondyloarthritis were treated. The mean duration of the diseases was 10 years. Infliximab was administered intravenously in a dose of 3 mg/kg body weight. A median of 6 doses

in 8 months was administered. Effectiveness was assessed in 19 patients that received three or more doses. RESULTS: Infliximab was effective in 16 patients (10 with rheumatoid arthritis, four with psoriasis and two with spondyloarthritis) and ineffective in three. In responsive patients, a reduction in the number of inflamed joints and morning stiffness and an improvement in functional capacity was observed. Fifteen of the 16 patients perceived an improvement in their health status. This answer was concordant with concomitant medical evaluation in 15. Patients that maintained the treatment felt very well, well or regular, whereas five of six patients that discontinued the treatment felt ill. Thirteen patients had adverse effects. Treatment was discontinued in two patients due to drug induced lupus, allergy in 2, hypertension in one, high costs in three and lack of response in three. CONCLUSIONS: Infliximab reduced arthritic activity in 16 of 19 patients with severe treatment refractory arthritis. (AU).

Descriptors: [Antibodies, Monoclonal/therapeutic use](#)
[Antirheumatic Agents/therapeutic use](#)
[Arthritis/drug therapy](#)
[-Arthritis, Psoriatic/drug therapy](#)
[Arthritis, Rheumatoid/drug therapy](#)
[Drug Resistance](#)
[Spondylarthritis/drug therapy](#)
[Treatment Outcome](#)
[Tumor Necrosis Factor/antagonists & inhibitors](#)

Limits: [Human](#)
[Male](#)
[Female](#)
[Adult](#)
[Middle Aged](#)

Responsible: CL12.1